文献速递中医内科中药与中成药合理使用

中药注射剂联合放疗治疗食管癌的贝叶斯网络Meta分析

The Optimal Chinese Herbal Injections for Use With Radiotherapy to Treat Esophageal Cancer: A Systematic Review and Bayesian Network Meta-Analysis.
PubMed 文献 · Front Pharmacol · 2019-01-04

本研究通过系统检索多个电子数据库,纳入55项随机对照试验(共4114例患者、12种中药注射剂),采用贝叶斯网络Meta分析比较不同中药注射剂联合放疗治疗食管癌的疗效与安全性。结果显示复方苦参注射液在提高临床有效率与改善体能状态方面最优,华蟾素与康艾注射液在提高1年及2年生存率方面更优,香菇多糖注射液可能有利于缓解不良反应。

要点

  • 复方苦参注射液联合放疗在提高临床有效率和改善体能状态方面可能最优。
  • 华蟾素与康艾注射液联合放疗在提高1年及2年生存率方面可能更优。
  • 香菇多糖注射液可能有利于缓解不良反应,复方苦参可能减少胃肠道反应和放射性食管炎。

核心结论

  • 当前临床证据表明,复方苦参注射液联合放疗在疗效与安全性方面可能是食管癌患者最可取且有益的选项。
  • 但鉴于纳入试验的样本量和方法学质量限制,研究结果应谨慎解读。

研究设计与样本

  • 系统评价与贝叶斯网络Meta分析,检索多个电子数据库至2017年3月15日,纳入55项随机对照试验,共12种中药注射剂、4114例参与者。

主要发现

  • 聚类分析结果提示复方苦参注射液在提高临床有效率和体能状态方面为最优中药注射剂治疗。
  • 华蟾素与康艾注射液在提高1年及2年生存率方面更优。
  • 香菇多糖注射液可能被认为是缓解不良反应的有利选择,复方苦参注射液可能通过减少胃肠道反应和放射性食管炎提供治疗获益。

关键数值与推荐

  • 纳入55项随机对照试验,涉及12种中药注射剂和4114例参与者。
  • 疗效与安全性结果以比值比(OR)及相应95%置信区间(CI)表示,通过Stata 13.1和WinBUGS 1.4软件计算。
  • 采用累积排序曲线下面积(SUCRA)对不同中药注射剂在各结局下的疗效与安全性进行排序。

临床怎么用

  • 对于食管癌放疗患者,可优先考虑复方苦参注射液以改善临床有效率和体能状态。
  • 若关注生存获益,可考虑联合华蟾素或康艾注射液。
  • 若需缓解不良反应,可考虑香菇多糖注射液;复方苦参注射液可能减少胃肠道反应和放射性食管炎。

局限性

  • 研究结果应谨慎解读,因纳入试验的样本量和方法学质量存在局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Ethnopharmacological relevance: Esophageal cancer is one of the most common human cancers, and its incidence is highly endemic in China. The combination of Chinese herbal injections (CHIs) and radiotherapy should be informed by the best available evidence. Aim of the study: To update and expand on previous work in order to compare and rank the efficacy and safety of CHIs in combination with radiotherapy to treat esophageal cancer. Materials and Methods: We searched several electronic databases to identify randomized controlled trials (RCTs) regarding CHIs to treat esophageal cancer from their inception to March 15, 2017. In a network meta-analysis (NMA), the bias of the included trials was assessed by two individuals independently in accordance with the Cochrane Handbook for Systematic Reviews of Interventions. Outcomes such as the clinical effectiveness rate, performance status, adverse reactions (ADRs), and survival rate were evaluated. We performed a random-effects NMA to obtain estimates of efficacy and safety outcomes, and we present these estimates as odds ratios (ORs) and corresponding 95% confidence intervals (CIs) calculated via Stata 13.1 and WinBUGS 1.4 software. Furthermore, the surface under cumulative the ranking curve (SUCRA) was used to rank the efficacy and safety of different CHIs in relation to each outcome. Results: Of 685 identified trials, 55 were eligible for inclusion in the study. These 55 trials included 12 CHIs and 4,114 participants. The cluster analysis results suggested that Compound kushen injection therapy is the optimal CHI treatment for patients with esophageal cancer in terms of improving the clinical effectiveness rate and performance status. Huachansu and Kangai injection are superior in improving 1-year and 2-year survival rates. Lentinan injection may be considered a favorable choice for reliving ADRs, and Compound kushen injection may provide treatment benefits by reducing both gastrointestinal reaction and radiation esophagitis. Conclusions: The current clinical evidence indicated that Compound kushen injection combined with radiotherapy is the most preferable and beneficial option for patients with esophageal cancer in terms of efficacy and safety. However, the results of our study should be interpreted with caution given the limitations of the sample size and the methodological quality of the included trials.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Zhang D, Ni M, Wu J, et al. The Optimal Chinese Herbal Injections for Use With Radiotherapy to Treat Esophageal Cancer: A Systematic Review and Bayesian Network Meta-Analysis. Front Pharmacol. 2019. PMID: 30662402. doi:10.3389/fphar.2018.01470

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。